RemeGen Co Ltd Class H 09995
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- HK$62.85
- Day Range
- HK$60.75–63.50
- 52-Week Range
- HK$60.00–123.10
- Bid/Ask
- HK$60.85 / HK$61.10
- Shares Outstanding
- 564.17M
- Market Cap
- HK$34.36B
- Volume/Avg
- 912,500 / 2M
Key Statistics
- Price/Earnings (Normalized)
- 5.59
- Price/Sales
- 3.94
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat severe diseases such as autoimmune diseases, oncology, and ophthalmology. It has its operations in China and the USA and derives the majority of its revenue from China.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Large Growth
- Total Number of Employees
- 3,146
- Website
- https://www.remegen.com
Valuation
Metric | 09995 |
|---|---|
Price/Earnings (Normalized) | 5.59 |
Price/Book Value | 3.41 |
Price/Sales | 3.94 |
Price/Cash Flow | 6.74 |
Price/Earnings
09995
Financial Strength
Metric | 09995 |
|---|---|
Quick Ratio | 4.19 |
Current Ratio | 4.82 |
Interest Coverage | 126.75 |
Quick Ratio
09995
Profitability
Metric | 09995 |
|---|---|
Return on Assets (Normalized) | 57.12% |
Return on Equity (Normalized) | 91.78% |
Return on Invested Capital (Normalized) | 67.44% |
Return on Assets
09995
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|kVK<$q | LOCK|jT^%m | $135B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|jLW&d%> | LOCK|!Z^$> | $99B | |||
| Moderna Inc MRNA | LOCK|#&g<cMx | LOCK|Y>R | $84B | |||
| argenx SE ADR ARGX | LOCK|^m&%!D | LOCK|Y#V | $59B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|@$fY!C | LOCK|&x | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|KJcqcr@L | LOCK|q<KD# | $31B | |||
| Incyte Corp INCY | LOCK|$hN^FJ^ | LOCK|p<$ | $24B | |||
| BioNTech SE ADR BNTX | LOCK|tLXLMr$ | LOCK|$pT | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|j$@mj^ | LOCK|$$qL | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|X$?^## | LOCK|$nd | $15B |